PubMed

Therapeutic roles of peroxisome proliferator-activated receptor agonists.

Staels B, Fruchart JC.

Diabetes. 2005 Aug;54(8):2460-70. Review.PMID: 16046315 [PubMed - indexed for MEDLINE]Related articlesFree article

PPAR ligands: are they potential agents for cardiovascular disorders?

Balakumar P, Rose M, Singh M.

Pharmacology. 2007;80(1):1-10. Epub 2007 May 10. Review.PMID: 17496434 [PubMed - indexed for MEDLINE]Related articles

Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists.

Gervois P, Fruchart JC, Staels B.

Int J Clin Pract Suppl. 2004 Oct;(143):22-9. Review.PMID: 16035393 [PubMed - indexed for MEDLINE]Related articles

PPAR dual agonists: are they opening Pandora's Box?

Balakumar P, Rose M, Ganti SS, Krishan P, Singh M.

Pharmacol Res. 2007 Aug;56(2):91-8. Epub 2007 Mar 14. Review.PMID: 17428674 [PubMed - indexed for MEDLINE]Related articles

Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.

Evans JL, Lin JJ, Goldfine ID.

Curr Diabetes Rev. 2005 Aug;1(3):299-307. Review.PMID: 18220606 [PubMed - indexed for MEDLINE]Related articles

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.

Touyz RM, Schiffrin EL.

Vascul Pharmacol. 2006 Jul;45(1):19-28. Epub 2006 Jun 16. Review.PMID: 16782410 [PubMed - indexed for MEDLINE]Related articles

PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

Gross B, Staels B.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):687-710. Review.PMID: 18054742 [PubMed - indexed for MEDLINE]Related articles

Atherosclerosis and cardiovascular risk reduction with PPAR agonists.

Kuusisto J, Andrulionyte L, Laakso M.

Curr Atheroscler Rep. 2007 Oct;9(4):274-80. Review.PMID: 18173954 [PubMed - indexed for MEDLINE]Related articles

Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.

Jay MA, Ren J.

Curr Diabetes Rev. 2007 Feb;3(1):33-9. Review.PMID: 18220654 [PubMed - indexed for MEDLINE]Related articles

New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).

Tjokroprawiro A.

Acta Med Indones. 2006 Jul-Sep;38(3):160-6. Review.PMID: 17119268 [PubMed - indexed for MEDLINE]Related articles

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.

Fiévet C, Fruchart JC, Staels B.

Curr Opin Pharmacol. 2006 Dec;6(6):606-14. Epub 2006 Sep 14. Review.PMID: 16973418 [PubMed - indexed for MEDLINE]Related articles

Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.

Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.

Am J Ther. 2007 Jan-Feb;14(1):49-62. Review.PMID: 17303976 [PubMed - indexed for MEDLINE]Related articles

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.PMID: 16168052 [PubMed - indexed for MEDLINE]Related articlesFree article

Measuring biomarkers to assess the therapeutic effects of PPAR agonists?

Chinetti-Gbaguidi G, Staels B.

Pharmacogenomics. 2007 Nov;8(11):1567-80. Review.PMID: 18034622 [PubMed - indexed for MEDLINE]Related articles

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J.

J Am Coll Cardiol. 2008 Sep 2;52(10):869-81. Epub 2008 Jul 2.PMID: 18755353 [PubMed - indexed for MEDLINE]Related articlesFree article

PPAR agonists and the metabolic syndrome.

Staels B.

Therapie. 2007 Jul-Aug;62(4):319-26. Epub 2007 Nov 6. Review.PMID: 17983557 [PubMed - indexed for MEDLINE]Related articles

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.

Mol Endocrinol. 2005 Jun;19(6):1593-605. Epub 2005 Apr 14.PMID: 15831517 [PubMed - indexed for MEDLINE]Related articlesFree article

Therapeutical effects of PPAR agonists assessed by biomarker modulation.

Chinetti-Gbaguidi G, Fruchart JC, Staels B.

Biomarkers. 2005 Nov;10 Suppl 1:S30-6. Review.PMID: 16298909 [PubMed - indexed for MEDLINE]Related articles

Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?

Gani OA.

Cardiovasc Diabetol. 2008 Mar 20;7:6.PMID: 18355413 [PubMed - indexed for MEDLINE]Related articlesFree article

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.PMID: 17519293 [PubMed - indexed for MEDLINE]Related articles